AstraZeneca plc (LON:AZN) received a GBX 5,300 ($68.45) target price from stock analysts at BNP Paribas in a research note issued on Monday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. BNP Paribas’ price objective would indicate a potential upside of 10.65% from the company’s previous close.
AZN has been the subject of several other research reports. HSBC Holdings plc restated a “reduce” rating and issued a GBX 4,100 ($52.95) price target on shares of AstraZeneca plc in a research note on Monday. UBS AG set a GBX 5,150 ($66.51) price target on AstraZeneca plc and gave the stock a “neutral” rating in a research note on Tuesday, June 27th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.37) price target on AstraZeneca plc and gave the stock a “sell” rating in a research note on Saturday, May 20th. Barclays PLC restated an “overweight” rating and issued a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a research note on Tuesday, August 1st. Finally, Citigroup Inc. restated a “buy” rating and issued a GBX 6,000 ($77.49) price target on shares of AstraZeneca plc in a research note on Friday, July 28th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of GBX 4,963.82 ($64.11).
AstraZeneca plc (AZN) opened at 4884.00 on Monday. The firm has a 50-day moving average price of GBX 4,593.39 and a 200-day moving average price of GBX 4,871.66. The company’s market cap is GBX 61.83 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.
AstraZeneca plc (LON:AZN) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $1.01. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. Equities research analysts anticipate that AstraZeneca plc will post $3.75 EPS for the current fiscal year.
In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.